Modality
Radioligand
MOA
CDK4/6i
Target
BTK
Pathway
NF-κB
NSCLC
Development Pipeline
Preclinical
~Jul 2015
→ ~Oct 2016
Phase 1
Jan 2017
→ Dec 2031
Phase 1Current
NCT05269150
1,255 pts·NSCLC
2017-01→2031-12·Terminated
1,255 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-12-145.7y awayInterim· NSCLC
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1
Termina…
Catalysts
Interim
2031-12-14 · 5.7y away
NSCLC
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05269150 | Phase 1 | NSCLC | Terminated | 1255 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| RHH-1969 | Roche | Approved | BET | |
| RHH-8482 | Roche | Phase 1 | BTK | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| VRT-5441 | Vertex Pharma | Phase 3 | GLP-1R |